A phase 1, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study of SR-8541A (ENPP1 inhibitor) Administered Orally as Monotherapy in Subjects with Advanced/Metastatic Solid Tumors

  • Body, Amy (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date26/02/24 → 25/02/29